Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Transcript

Why It Matters

The restructuring strengthens Accendra’s balance sheet and positions its high‑margin home‑based care segments for accelerated growth, reassuring investors amid a volatile payor landscape.

Key Takeaways

• Revenue down 6.8%, would be flat without payor exit
• Adjusted EBITDA $58M, meeting expectations
• Sleep therapy segment grew over 4% with higher order value
• Balance sheet transaction reduces debt up to $115M, extends maturities
• New exclusive soft‑goods agreement secures future revenue

Pulse Analysis

Accendra Health’s first‑quarter results highlight the growing importance of pure‑play home‑based care providers in a fragmented reimbursement environment. By shedding a large commercial payor and completing the associated equipment sale, the company eliminated a volatile revenue stream while preserving core margins. This transition, combined with a shift from 19% gross margins to nearly 50%, underscores how strategic divestitures can unlock value and improve operational focus, a trend echoed across the DME and tele‑health sectors as providers seek scalable, high‑margin business models.

Growth is now being driven by niche therapeutic categories, particularly sleep therapy, which posted over 4% year‑over‑year growth and higher average order values thanks to the Sleep Journey program and the newly piloted Sleep Center of Excellence. These initiatives improve patient adherence, reduce attrition, and create a referral pipeline that can be replicated across urology, ostomy and other home respiratory products. The company’s emphasis on centralized, expert‑led onboarding aligns with broader industry moves toward standardized care pathways that enhance outcomes while containing costs.

The balance‑sheet optimization announced in the call is a decisive step toward financial resilience. By retiring 2027 maturities, issuing first‑ and second‑lien notes through 2033, and securing a $300 million revolver, Accendra reduces debt by up to $115 million and extends its financing horizon, mitigating refinancing risk and supporting future acquisitions. Although interest expense is projected to rise by $40 million, the added liquidity and longer tenor provide flexibility to invest in growth initiatives and navigate potential payer reforms. Investors will watch the second‑half performance closely, as the company expects the majority of its adjusted EBITDA to materialize during that period.